GlassScriptPhysician profile
Tywaun K Tillman
NPI 1710915012
$10,464.40
in general payments reported to CMS, 2019-2025
31 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $536 · 2021: $284 · 2022: $831 · 2023: $885 · 2024: $4,933 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,429 · Travel and Lodging: $2,592 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,428.62 |
| Travel and Lodging | $2,592.04 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,875.92 | 2024 | Indigo System, Penumbra System |
| Abbott Laboratories | $1,141.05 | 2019-2025 | Gallant, Mitraclip, Diamondback Coronary |
| Medtronic, INC. | $1,014.76 | 2021-2025 | Reveal Linq, In.Pact Admiral, Micra |
| E.R. Squibb & Sons, L.L.C. | $765.39 | 2022-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $393.89 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $379.33 | 2019-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $314.42 | 2019-2025 | |
| Abiomed | $268.94 | 2019-2024 | Impella |
| Janssen Pharmaceuticals, INC | $247.15 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $239.64 | 2022-2023 | Verquvo |
| Cardiovascular Systems INC. | $236.49 | 2019-2022 | |
| Scpharmaceuticals INC. | $233.00 | 2025 | |
| Boston Scientific Corporation | $224.42 | 2022-2025 | Farapulse, Watchman Flx |
| Pfizer INC. | $219.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.16 | 2024-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $137.47 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $123.97 | 2025 | |
| Medtronic Vascular, INC. | $68.78 | 2019-2020 | |
| Biosense Webster, INC. | $61.32 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $58.86 | 2025 | Opsumit |
| Amgen INC. | $58.62 | 2025 | Repatha |
| Infobionic, INC | $37.86 | 2025 | Mome Device |
| Esperion Therapeutics, INC. | $35.18 | 2025 | Nexletol |
| Irhythm Technologies, INC. | $34.29 | 2019 | |
| Becton, Dickinson and Company | $32.36 | 2024 | Rotarexs 6 F X 135 Cm, Lutonix Drug Coated Balloon |
| Philips North America LLC | $26.12 | 2025 | Extended Holter |
| Novo Nordisk INC | $21.72 | 2024 | Ozempic |
| Preventice Services, LLC | $18.16 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.18 | 2025 | Lifevest |
| Azurity Pharmaceuticals, INC. | $15.15 | 2025 | |
| Chiesi USA, INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tywaun Tillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.